FDA Extends Sanofi Sarclisa Subcutaneous Review by Three Months for Multiple Myeloma Treatment

Key Takeaways

• FDA has extended the review period for Sanofi’s Sarclisa subcutaneous formulation by up to three months
• The subcutaneous version would offer patients a more convenient alternative to the current intravenous administration
• Approval would cover all existing multiple myeloma indications currently approved for Sarclisa IV

---

Paris, April 22, 2026 — The U.S. Food and Drug Administration has extended the target action date for Sanofi’s biologics license application for Sarclisa (isatuximab-irfc) subcutaneous formulation by up to three months, the French pharmaceutical company announced today.

Regulatory Review Extension

The extension affects Sanofi’s application for Sarclisa subcutaneous in combination with approved standard-of-care regimens for treating multiple myeloma patients across all currently approved U.S. indications for the intravenous formulation.

This regulatory delay is common in the pharmaceutical industry as the FDA conducts thorough reviews of new drug applications, particularly for oncology treatments where patient safety is paramount.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Multiple Myeloma Treatment Landscape

Sarclisa is already approved in its intravenous form for multiple myeloma treatment. The subcutaneous formulation represents a significant advancement in patient care, potentially offering:

• Improved convenience: Shorter administration times compared to IV infusion
• Enhanced patient experience: Reduced time spent in clinical settings
• Maintained efficacy: Same therapeutic benefits as the IV formulation

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Implications

Multiple myeloma affects approximately 35,000 Americans annually, making it the second most common blood cancer. The subcutaneous formulation could capture additional market share by appealing to patients and healthcare providers seeking more convenient treatment options.

The three-month extension, while disappointing for patients awaiting this treatment option, demonstrates the FDA’s commitment to thorough safety and efficacy evaluation. Sanofi continues to work closely with regulators to address any outstanding questions regarding the application.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for pharmaceutical intelligence pricing, access, and launch sequencing.

Looking Ahead

The extended timeline pushes the potential approval date further into 2026, affecting Sanofi’s commercial timeline for this important oncology asset. However, the company remains confident in the application’s eventual approval based on clinical trial data supporting the subcutaneous formulation’s safety and efficacy profile.

---

Frequently Asked Questions

What does this FDA extension mean for multiple myeloma patients?

Patients will need to wait an additional three months for potential access to the more convenient subcutaneous version of Sarclisa, though the current intravenous formulation remains available for treatment.

When will Sarclisa subcutaneous be available if approved?

With the three-month extension, the earliest potential approval would be later in 2026, followed by commercial launch pending FDA clearance.

How does subcutaneous Sarclisa compare to the current IV version?

The subcutaneous formulation offers the same therapeutic benefits as IV Sarclisa but with more convenient administration, shorter treatment times, and reduced clinic visits for patients.

Related coverage

• Vanda tradipitant update: FDA re-review extends to Dec. 5, 2025
• GSK Blenrep wins FDA approval in relapsed multiple myeloma
• Sanofi pipeline pdf: Dupixent, Lantus and 2026 catalysts